Sustainability Investment News Order reprints | Send it to a friend | Print it | Save it

February 23, 2009

SRI Fund is Category King for January 2009
by Robert Kropp

Eventide's Gilead Fund is designated top multi-cap growth fund by Wall Street Journal

SocialFunds.com — For the month of January, 2009, The Wall Street Journal designated the Eventide Gilead Fund (ETGLX) as the top-performing multi-cap growth fund. Funds are ranked by year-to-date total returns.

During the month of January, the Gilead Fund showed a 2.9% increase in value, outperforming the S&P 500 Index by a wide margin. Data published in the Journal indicates that only two other multi-cap growth funds increased in value during the time period.

The Gilead Fund is a multi-cap growth fund that seeks to provide long-term capital appreciation. It invests in a broad range of equity securities without limitation to market capitalization, with the majority of its holdings falling into the mid- and small-cap range. As of February 1, 2009, the Fund has $0.8 million in assets under management.

The advisor for the Fund is Eventide Asset Management,a Boston-based investment advisory firm that offers no-load mutual funds for both individual and institutional investors. The Gilead Fund, launched on July 1, 2008, is Eventide's first mutual fund.

Eventide reviews potential investments in an attempt to ensure that the securities chosen for the Gilead Fund are of companies that are not inconsistent with core Christian ethical values. Specifically, Eventide seeks to avoid investing in companies that support abortion, gambling, pornography, tobacco, alcohol, weaponry, violent video gaming, environmentally irresponsible actions, or animal cruelty.

Currently, the top three stock positions in the Fund are AMAG Pharmaceuticals, Bristow Group, and El Paso Corp.

Sustainability Investment News Order reprints | Send it to a friend | Print it | Save it

February 23, 2009

SRI Fund is Category King for January 2009
by Robert Kropp

Eventide's Gilead Fund is designated top multi-cap growth fund by Wall Street Journal

SocialFunds.com — For the month of January, 2009, The Wall Street Journal designated the Eventide Gilead Fund (ETGLX) as the top-performing multi-cap growth fund. Funds are ranked by year-to-date total returns.

During the month of January, the Gilead Fund showed a 2.9% increase in value, outperforming the S&P 500 Index by a wide margin. Data published in the Journal indicates that only two other multi-cap growth funds increased in value during the time period.

The Gilead Fund is a multi-cap growth fund that seeks to provide long-term capital appreciation. It invests in a broad range of equity securities without limitation to market capitalization, with the majority of its holdings falling into the mid- and small-cap range. As of February 1, 2009, the Fund has $0.8 million in assets under management.

The advisor for the Fund is Eventide Asset Management,a Boston-based investment advisory firm that offers no-load mutual funds for both individual and institutional investors. The Gilead Fund, launched on July 1, 2008, is Eventide's first mutual fund.

Eventide reviews potential investments in an attempt to ensure that the securities chosen for the Gilead Fund are of companies that are not inconsistent with core Christian ethical values. Specifically, Eventide seeks to avoid investing in companies that support abortion, gambling, pornography, tobacco, alcohol, weaponry, violent video gaming, environmentally irresponsible actions, or animal cruelty.

Currently, the top three stock positions in the Fund are AMAG Pharmaceuticals, Bristow Group, and El Paso Corp.

Sustainability Investment News Order reprints | Send it to a friend | Print it | Save it

February 23, 2009

SRI Fund is Category King for January 2009
by Robert Kropp

Eventide's Gilead Fund is designated top multi-cap growth fund by Wall Street Journal

SocialFunds.com — For the month of January, 2009, The Wall Street Journal designated the Eventide Gilead Fund (ETGLX) as the top-performing multi-cap growth fund. Funds are ranked by year-to-date total returns.

During the month of January, the Gilead Fund showed a 2.9% increase in value, outperforming the S&P 500 Index by a wide margin. Data published in the Journal indicates that only two other multi-cap growth funds increased in value during the time period.

The Gilead Fund is a multi-cap growth fund that seeks to provide long-term capital appreciation. It invests in a broad range of equity securities without limitation to market capitalization, with the majority of its holdings falling into the mid- and small-cap range. As of February 1, 2009, the Fund has $0.8 million in assets under management.

The advisor for the Fund is Eventide Asset Management,a Boston-based investment advisory firm that offers no-load mutual funds for both individual and institutional investors. The Gilead Fund, launched on July 1, 2008, is Eventide's first mutual fund.

Eventide reviews potential investments in an attempt to ensure that the securities chosen for the Gilead Fund are of companies that are not inconsistent with core Christian ethical values. Specifically, Eventide seeks to avoid investing in companies that support abortion, gambling, pornography, tobacco, alcohol, weaponry, violent video gaming, environmentally irresponsible actions, or animal cruelty.

Currently, the top three stock positions in the Fund are AMAG Pharmaceuticals, Bristow Group, and El Paso Corp.

Sustainability Investment News Order reprints | Send it to a friend | Print it | Save it

February 23, 2009

SRI Fund is Category King for January 2009
by Robert Kropp

Eventide's Gilead Fund is designated top multi-cap growth fund by Wall Street Journal

SocialFunds.com — For the month of January, 2009, The Wall Street Journal designated the Eventide Gilead Fund (ETGLX) as the top-performing multi-cap growth fund. Funds are ranked by year-to-date total returns.

During the month of January, the Gilead Fund showed a 2.9% increase in value, outperforming the S&P 500 Index by a wide margin. Data published in the Journal indicates that only two other multi-cap growth funds increased in value during the time period.

The Gilead Fund is a multi-cap growth fund that seeks to provide long-term capital appreciation. It invests in a broad range of equity securities without limitation to market capitalization, with the majority of its holdings falling into the mid- and small-cap range. As of February 1, 2009, the Fund has $0.8 million in assets under management.

The advisor for the Fund is Eventide Asset Management,a Boston-based investment advisory firm that offers no-load mutual funds for both individual and institutional investors. The Gilead Fund, launched on July 1, 2008, is Eventide's first mutual fund.

Eventide reviews potential investments in an attempt to ensure that the securities chosen for the Gilead Fund are of companies that are not inconsistent with core Christian ethical values. Specifically, Eventide seeks to avoid investing in companies that support abortion, gambling, pornography, tobacco, alcohol, weaponry, violent video gaming, environmentally irresponsible actions, or animal cruelty.

Currently, the top three stock positions in the Fund are AMAG Pharmaceuticals, Bristow Group, and El Paso Corp.